The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Access, Cost, and Follow-Up Questions for People With Mild Cognitive Impairment

Learn what PrecivityAD2 costs, who can order it, and which follow-up tests to discuss for MCI.

Learn what PrecivityAD2 costs, who can order it, and which follow-up tests to discuss for MCI.

Tau PET scanning just got a second FDA-approved option, but access, cost, and evidence gaps still matter most for younger-onset cases.

A new tau PET scan just approved for Alzheimer's workups could cut years off the diagnostic wait many younger-onset families face.

A newly cleared blood test gives symptomatic adults as young as 40 a faster path to an amyloid-pathology answer than PET or spinal tap.

A blood test now cleared down to age 40 changes what younger-onset Alzheimer's families can ask for at their next appointment.

A clear breakdown of PrecivityAD2's new age-40 clearance, its accuracy limits, and where families can actually access and afford it.

A blood test now cleared at age 40 gives younger-onset Alzheimer's families a path to answers they didn't have before.

Here's exactly how family caregivers can still reach HHS and the Advisory Council after the Alzheimer's plan's comment window closed.

Tracks exactly where HHS stands on the 2026-2035 Alzheimer's plan rewrite and what caregivers should watch next, not guess at.

Starting Leqembi now means weekly home injections from day one, not 18 months of IV visits first — but eligibility and MRI monitoring rules are unchanged.
HelpDementia.com
Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance
© 2026 HelpDementia.com. All rights reserved.
Educational information only. It is not medical advice and does not replace care from a qualified clinician.